Omalizumab in severe allergic asthma

10th May 2013 by Louise Hudman

This guideline advises that Omalizumab can be used in the treatment of asthma. It is a monoclonal antibody that binds to IgE and is given every 2 to 4 weeks subcut. We may start seeing patients treated with this, so worth knowing about it. Treatment is to be started and maintained by specialists only. Quite a lot of criteria must be met before use, so it’ll only be used in the most severe asthma, where allergy testing has been positive.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"LocumDeck does everything you want it to do in an instant and with audit trails.

I absolutely love the facility for receiving Locum's invoices and the facility for signing the Pension Forms electronically and they are then instantly sent with an audit trail! It is fabulous!

You are notified the moment a Locum GP adds availability which is just fantastic, I spend a lot of time just chasing agencies to see if they have availability, so to be notified the moment availability is advertised is a new concept and very welcome! I have no hesitation in recommending LocumDeck - it has already eased my workload!"

Sue, Practice Manager in Portsmouth

See the full list of features within our NASGP membership plans

Membership